Peptok
peptides profiled research articles
Growth Hormone Secretagogue

CJC-1295 + Ipamorelin (Combo)

Formula: Combination product

P
Written by Peptok Research
Reviewed by Medical Advisory BoardLast updated: Jan 2026

Quick Stats

Evidence Strength1/10 (Low)

Based on number and quality of indexed studies

Community Popularity8/10 (High)

Based on search volume and community interest

Legal Status

⚖️ Not FDA-approved

Type

Growth Hormone Secretagogue

Route

Subcutaneous injection

Half-life

CJC-1295 (DAC): ~8 days. Ipamorelin: ~2 hours

Medical Disclaimer

This content is for informational and research purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before making decisions about peptide use or any medical treatment. Individual results may vary.

Overview

CJC-1295 + Ipamorelin Stack is often used to increase growth hormone levels. CJC-1295 boosts growth hormone release by binding to the growth hormone-releasing hormone (GHRH) receptor, while Ipamorelin amplifies this effect by also suppressing somatostatin, a growth hormone inhibitor.

Quick Summary

  • 🧬
    What it is:CJC-1295 + Ipamorelin Stack is often used to increase growth hormone levels.
  • 🎯
    Primary use:Growth Hormone Secretagogue applications — see benefits section for details.
  • 📊
    Evidence level:Preliminary — Mostly anecdotal or very early-stage research (1 indexed papers)
  • Bottom line:Very early research phase. Approach with appropriate caution; long-term safety is unknown.

The CJC-1295 + Ipamorelin combination is a popular strategy for those seeking to elevate their growth hormone (GH) levels. Unlike direct GH administration, this stack works by stimulating the body's own GH production. This approach aims to provide a more natural and pulsatile release of GH.

Both CJC-1295 and Ipamorelin are Growth Hormone Secretagogue peptides, meaning they encourage the pituitary gland to release more GH. They achieve this through distinct but synergistic mechanisms, potentially leading to a greater overall effect than either compound used alone. This stack is often compared to other GH-boosting strategies like MK-677, but it operates through different pathways.

The appeal of CJC-1295 + Ipamorelin lies in its potential to enhance GH levels without the potential downsides associated with direct GH injections. Many users report improvements in sleep quality, muscle recovery, and body composition, although rigorous scientific evidence is still developing.

How CJC-1295 + Ipamorelin Stack Works

CJC-1295 and Ipamorelin work together to increase growth hormone release. CJC-1295 is a Growth Hormone Releasing Hormone (GHRH) analog. It binds to the GHRH receptor on pituitary cells, stimulating the release of GH. However, the natural GHRH has a short half-life, meaning it is quickly broken down in the body. CJC-1295 is modified to extend its half-life, leading to a longer-lasting GH pulse.

Ipamorelin is a selective Growth Hormone Secretagogue (GHS). It mimics ghrelin, a hormone that stimulates GH release. Ipamorelin binds to the ghrelin receptor (also known as the GH secretagogue receptor) in the pituitary gland. This binding triggers GH release. Ipamorelin also has the advantage of suppressing somatostatin, a hormone that inhibits GH release. By reducing somatostatin activity, Ipamorelin further enhances GH secretion.

The combination of CJC-1295 and Ipamorelin aims to provide both a strong initial stimulus (Ipamorelin) and a sustained release (CJC-1295). The idea is that Ipamorelin provides an immediate boost, while CJC-1295 maintains elevated GH levels for a longer duration. This pulsatile release mimics the natural pattern of GH secretion, which may be more physiologically beneficial than constant GH elevation.

What the Research Actually Shows

Muscle Growth: Animal studies have shown that GHRH analogs can increase muscle mass. However, direct evidence specifically examining the CJC-1295 + Ipamorelin stack's effect on muscle growth in humans is limited. Anecdotal reports suggest potential benefits, but controlled clinical trials are needed to confirm these observations. Evidence Grade: Preliminary.

Fat Loss: Some studies suggest that increased GH levels can promote fat loss. GH influences lipolysis, the breakdown of fats, and can shift metabolism towards using fat as an energy source. A small human trial showed a trend towards fat loss with GHRH analogs, but the results were not statistically significant. More research is needed to determine if the CJC-1295 + Ipamorelin stack leads to clinically relevant fat loss. Evidence Grade: Preliminary.

Improved Sleep: GH is released in pulses, primarily during sleep. Some users report improved sleep quality with CJC-1295 + Ipamorelin. Studies investigating the effect of GH on sleep architecture have shown mixed results. A small study showed that GH administration can increase slow-wave sleep, the deepest stage of sleep. However, it is unclear if the CJC-1295 + Ipamorelin stack has a similar effect. Evidence Grade: Preliminary.

Enhanced Recovery: GH plays a role in tissue repair and regeneration. It stimulates the production of insulin-like growth factor 1 (IGF-1), which is crucial for muscle protein synthesis and recovery. There is limited direct evidence examining the effect of CJC-1295 + Ipamorelin on recovery from exercise or injury. Some users report faster recovery times, but these are anecdotal observations. Further research is needed to determine if this stack truly enhances recovery. Evidence Grade: Preliminary.

Anti-Aging Effects: GH levels decline with age. Some believe that increasing GH levels can reverse some of the effects of aging. While GH therapy has shown some benefits in older adults, such as increased muscle mass and bone density, it also carries risks. The long-term effects of CJC-1295 + Ipamorelin on aging are unknown. Evidence Grade: Preliminary.

CJC-1295 + Ipamorelin Stack vs. MK-677

Both CJC-1295 + Ipamorelin and MK-677 are used to increase GH levels, but they work through different mechanisms. CJC-1295 + Ipamorelin stimulates the pituitary gland to release GH, while MK-677 mimics ghrelin to promote GH release and also increases appetite.

Here's a breakdown of the key differences:

  • Mechanism: CJC-1295 + Ipamorelin stimulates the pituitary gland directly. MK-677 mimics ghrelin, affecting both GH release and appetite.
  • Administration: CJC-1295 + Ipamorelin is typically administered via subcutaneous injection. MK-677 is taken orally.
  • Pulsatility: CJC-1295 + Ipamorelin aims to mimic the natural pulsatile release of GH. MK-677 can lead to a more sustained elevation of GH levels.
  • Side Effects: Both can cause water retention. MK-677 is more likely to increase appetite.
  • Regulation: Both are research chemicals and not approved for human use by regulatory agencies.

The choice between CJC-1295 + Ipamorelin and MK-677 depends on individual preferences and goals. Some prefer the pulsatile release of GH achieved with CJC-1295 + Ipamorelin, while others find the convenience of oral MK-677 more appealing. The increased appetite associated with MK-677 can be beneficial for those looking to bulk up, but undesirable for those trying to lose weight.

The Honest Limitations

The research on CJC-1295 + Ipamorelin is limited. While there are studies on GHRH analogs and GH secretagogues individually, there is a lack of robust clinical trials specifically evaluating the combined effects of CJC-1295 + Ipamorelin.

Here are some key limitations to consider:

  • Lack of Large-Scale Human Trials: Most of the available evidence is based on small studies or animal models. Larger, well-designed human trials are needed to confirm the efficacy and safety of this stack.
  • Short-Term Studies: Many studies are conducted over a relatively short period (e.g., a few weeks or months). The long-term effects of CJC-1295 + Ipamorelin on GH levels, body composition, and overall health are largely unknown.
  • Individual Variability: The response to CJC-1295 + Ipamorelin can vary significantly from person to person. Factors such as age, genetics, and lifestyle can influence the effectiveness of this stack.
  • Regulatory Status: CJC-1295 and Ipamorelin are research chemicals and are not approved for human use by regulatory agencies. This means that the quality and purity of these compounds can vary depending on the source.
  • Potential Side Effects: While generally considered safe, CJC-1295 + Ipamorelin can cause side effects such as injection site reactions, water retention, and increased prolactin levels in some individuals. The long-term safety profile is not fully established.

Timing for Optimal Effect

The timing of CJC-1295 + Ipamorelin administration can influence its effectiveness. GH is naturally released in pulses, with the largest pulse occurring during sleep. To maximize the benefits of this stack, it is generally recommended to administer it close to bedtime.

Here's a suggested timing strategy:

  • Administer the injection 30-60 minutes before bedtime. This allows the peptides to enter the bloodstream and stimulate GH release during sleep, when the body is naturally primed for GH secretion.
  • Avoid eating a large meal close to the injection. Food intake, especially carbohydrates, can blunt GH release. It is best to administer the injection on an empty stomach or after a light meal.
  • Consider splitting the dose. Some users find that splitting the daily dose into two smaller injections (e.g., one in the morning and one before bed) provides a more consistent GH release. However, this may also increase the frequency of injections.
  • Be consistent with the timing. Maintaining a consistent injection schedule can help to optimize GH levels over time.

It's important to note that these are general recommendations. The optimal timing may vary depending on individual factors such as metabolism, sleep patterns, and activity level. Experimenting with different timing strategies may be necessary to find what works best.

Benefits & Evidence

Synergistic GH release (greater than either alone)

Moderate Evidence

1 studies · 1 human trial

Improved sleep quality

Moderate Evidence

1 studies · 0 human trials

Enhanced fat loss

Preliminary

1 studies · 0 human trials

Increased lean muscle mass

Preliminary

1 studies · 0 human trials

Better recovery from training

Preliminary

1 studies · 0 human trials

Anti-aging effects on skin and hair

Preliminary

1 studies · 0 human trials

Who Uses CJC-1295 + Ipamorelin (Combo)?

Research enthusiasts

Preliminary

Emerging therapeutic applications being studied

Biohackers

Anecdotal

Exploring optimization potential

Not recommended if:

Pregnant or nursing, history of hormone-sensitive cancers, active autoimmune conditions, or pediatric patients. Always consult a physician before starting any peptide protocol.

Dosage Guide

Protocol by Experience Level

ExperienceDoseFrequencyCycleRoute
Beginner100 mcgDaily or EOD4–6 wks, 2 wks offSubQ injection
Intermediate200 mcgDaily4–6 wks, 2 wks offSubQ injection
Advanced300 mcgDaily (split dose)4–6 wks, 2 wks offSubQ injection

Standard Protocol

CJC-1295: 100-300 mcg + Ipamorelin: 100-300 mcg per injection. Once daily before bed.

Notes

Most effective on an empty stomach before bed — aligns with natural GH pulse during sleep. The CJC-1295 with DAC version has a longer half-life (weekly dosing possible). Without DAC (mod GRF 1-29), dose 1-3 times daily. This is considered the "gold standard" starter GH peptide stack.

Route

Subcutaneous injection

Half-life

CJC-1295 (DAC): ~8 days. Ipamorelin: ~2 hours

Molecular Weight

CJC-1295: ~3367 g/mol. Ipamorelin: ~711 g/mol

Disclaimer

This information is for educational purposes only. Dosage information is derived from research literature and community reports. Always consult a qualified healthcare provider before using any peptide.

What the Community Reports

Community data coming soon

We're aggregating Reddit discussions for CJC-1295 + Ipamorelin (Combo).

Safety Profile

Regulatory Status

Not FDA-approved. Research chemicals. Available through some clinics and compounding pharmacies. Banned by WADA.

Common

  • Water retention
  • Increased hunger (mild)
  • Tingling/numbness in hands

Rare

  • Headache
  • Injection site irritation

Serious

No serious adverse events reported in available literature.

Pregnancy: ❌ Not recommended — no safety dataKnown Interactions: 3 documented stacks
Available

Your Ad could be placed here.

Reach researchers and enthusiasts.

Contact Us

Research

Mechanism of Action

CJC-1295 binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release. Ipamorelin binds to ghrelin/GHS receptors, amplifying the GH pulse and suppressing somatostatin. Together, they create a dual-input signal: CJC-1295 provides the sustained baseline stimulation (long half-life) while ipamorelin creates acute GH pulses (short half-life). The synergy typically produces 3-5x more GH than either peptide alone.

Search Volume Trend

Rank #1
12 months agoPresent
Clinical Trial2006

Modified GRF(1-29) and ghrelin mimetic combinations for GH release

Journal of Clinical Endocrinology & Metabolism · Veldhuis JD, et al.

Common Stacks

Peptides frequently combined together for synergistic effects.

MK-677

Body Composition

Growth hormone secretagogue stack for enhanced recovery and body composition

BPC-157

Recovery & Healing

Complements systemic healing with localized tissue repair

TB-500

Recovery & Healing

Synergistic tissue repair — BPC-157 handles GI/tendons while TB-500 targets systemic healing

Peptok is editorially independent. Our research profiles are evidence-based and regularly updated. Sponsored content is always clearly labeled. Read our Editorial Policy.